Credit Suisse analyst Judah Frommer assumed coverage of BioMarin with an Outperform rating and $120 price target. The analyst made no changes to the firm’s prior rating, target price, or estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin should be bought on any weakness, says Piper Sandler
- BioMarin price target lowered to $120 from $125 at Guggenheim
- BioMarin price target raised to $127 from $112 at Baird
- BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
- BioMarin sees FY23 adjusted EPS $1.80-$2.05, consensus 95c